Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q92187
UPID:
SIA8D_HUMAN
Alternative names:
Alpha-2,8-sialyltransferase 8D; Polysialyltransferase-1; Sialyltransferase 8D; Sialyltransferase St8Sia IV
Alternative UPACC:
Q92187; A8KA07; G3V104; Q8N1F4; Q92693
Background:
CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase, also known as Alpha-2,8-sialyltransferase 8D, plays a crucial role in the synthesis of polysialic acid (PSA). PSA is vital for the plasticity of neural cells, as it is present on the embryonic neural cell adhesion molecule (N-CAM). This enzyme's activity is essential for the polycondensation of alpha-2,8-linked sialic acid, a key process in neural development and function.
Therapeutic significance:
Understanding the role of CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase could open doors to potential therapeutic strategies. Its pivotal function in neural cell plasticity suggests its involvement in neural repair and regeneration, making it a target of interest in neurodegenerative disease research.